GlobeNewswire·Nov 11, 2026, 4:05 PM ET

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma

Oncolytics Biotech and Coherus Oncology entered a clinical supply agreement to evaluate pelareporep combined with toripalimab (LOQTORZI) in patients with squamous cell anal carcinoma (SCAC).
The study is expected to begin in the first quarter of 2027 at a premier U.S. cancer center once identified.
Patient enrollment will target individuals who have progressed on current first-line standard-of-care chemotherapy & checkpoint inhibition, a population with no approved second-line therapy.
Coherus will provide LOQTORZI to Oncolytics, which will partner with the institution sponsoring the clinical study.
The combination aims to leverage pelareorep's activation of toll-like receptor 3 & formation of tertiary lymphoid structures to enhance the antitumor activity of toripalimab's PD-1 blockade.
Previous data indicates the combination increases HPV-16-specific T cell clones & tumor-infiltrating lymphocytes in SCAC patients.
Success in SCAC may serve as a foundation for broader evaluation of this combination across other HPV-associated cancers.
Pelareorep has been administered to over 1,200 patients & holds FDA Fast Track designation for colorectal, anal, & pancreatic cancers.
Toripalimab is the only FDA-approved PD-1 inhibitor indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.

Company: Oncolytics Biotech, Inc.
Keywords: Nasdaq:ONCY, Oncolytics Biotech, Inc., oncology, oncolytic virus, oncology immunology, immunology, scac